Observational studyJournal of clinical oncology : official journal of the American Society of Clinical Oncology2018
Development and Validation of a Risk Prediction Model for Acute Kidney Injury After the First Course of Cisplatin.
Observational study in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 1 synthesis or guideline pooled it, 124 citations in OpenAlex.
- Characterization of Risk Prediction Models for Acute Kidney Injury: A Systematic Review and Meta-analysis.JAMA network open · 2023Pooled it
- Trial
- Predictions of cisplatin-induced hyponatremia in patients with malignancy: a retrospective cohort survey of all cisplatin administration in clinical practice.Clinical and experimental nephrology · 2026Article
- Prediction of Acute Kidney Injury in Oncology: From Clinical Risk Scores to AI-Enabled Precision Onco-Nephrology.Cancers · 2026Review
- Potential Benefit of Sodium-Glucose Cotransporter 2-Inhibitors in Cisplatin-Associated Nephrotoxicity Among Patients With Cancer Having Diabetes Mellitus.Kidney international reports · 2026Article
- The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroup.Nature reviews. Nephrology · 2026Review
- Predicting Acute Kidney Injury with Nephrotoxic Burden in Noncritical Patients: An Internal and External Validation Study.Kidney360 · 2026Article
- Mannitol versus furosemide for prevention of cisplatin-induced nephrotoxicity in a multicenter retrospective cohort study.Scientific reports · 2025Observational
- Systematic Review and Meta-Analysis of Machine Learning Models for Acute Kidney Injury Risk Classification.Journal of the American Society of Nephrology : JASN · 2025Article
- Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data.JAMA oncology · 2025Article
- External validation and comparison of clinical prediction models for cisplatin-associated acute kidney injury: a single-centre retrospective study.Journal of pharmaceutical health care and sciences · 2025Article
- Effects of RAAS blockade on acute kidney injury in head and neck cancer patients post-chemoradiotherapy.BMC nephrology · 2025Article
- A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury.Signal transduction and targeted therapy · 2025Article
- Integrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practice.EClinicalMedicine · 2025Review
- Updating Predictive Model for Cisplatin-Induced Acute Kidney Injury: Incorporating Concomitant Medications and the Standard Supportive Care.International journal of nephrology · 2025Article
- Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information.Clinical and translational science · 2025Article
- Evaluation of urinary vanin-1 for the early prediction of cisplatin-induced acute kidney injury during neoadjuvant chemotherapy for esophageal cancer.Cancer chemotherapy and pharmacology · 2024Article
- Article
- Evaluation of a new score associated with acute kidney injury in patients treated with cisplatin based EXTREME regimen.BMC cancer · 2024Article
- Derivation and external validation of a simple risk score for predicting severe acute kidney injury after intravenous cisplatin: cohort study.BMJ (Clinical research ed.) · 2024Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Purpose Cisplatin-associated acute kidney injury (C-AKI) is common. We sought to develop and validate a predictive model for C-AKI after the first course of cisplatin. Methods Clinical and demographic data were collected on patients who received cisplatin between 2000 and 2016 at two cancer centers. C-AKI was defined as a 0.3 mg/dL rise in serum creatinine within 14 days of receiving cisplatin. Using multivariable logistic regression models with C-AKI as the primary outcome, we created a scoring model from the development cohort (DC) and tested it in the validation cohort (VC). Results C-AKI occurred in 13.6% of 2,118 patients in the DC and in 11.6% of 2,363 patients in the VC. Factors significantly associated with C-AKI included age 61 to 70 years (odds ratio [OR], 1.64 [95% CI, 1.21 to 2.23]; P = .001) and 71 to 90 years (OR, 2.97 [95% CI, 2.06 to 4.28]; P < .001) compared with ≤ 60 years; cisplatin dose 101 to 150 mg (OR, 1.58 [95% CI, 1.14 to 2.19]; P = .007) and > 150 mg (OR, 3.73 [95% CI, 2.68 to 5.20]; P < .001) compared with ≤ 100 mg; a history of hypertension (OR, 2.10 [95% CI, 1.54 to 2.72]; P < .001) compared with no hypertension; and serum albumin 2.0 to 3.5 g/dL (OR, 2.21 [95% CI, 1.62 to 3.03]; P < .001) compared with > 3.5 g/dL. The baseline estimated glomerular filtration rate was not significantly associated with the risk of C-AKI. The c-statistics of the score-based model in the DC and the VC were 0.72 (95% CI, 0.69 to 0.75) and 0.70 (95% CI, 0.67 to 0.73), respectively. Scores of 0, 3.5, and 8.5 were associated with a probability of C-AKI of 0.03 (95% CI, 0.03 to 0.05), 0.12 (95% CI, 0.11 to 0.14), and 0.51 (95% CI, 0.43 to 0.60), respectively. Conclusion A score-based model created by using the patient's age, cisplatin dose, hypertension, and serum albumin is predictive of C-AKI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.